Pulmonary Langerhans Cell Histiocytosis
Conditions
Brief summary
Pulmonary Langerhans cell histiocytosis (PLCH) is a rare disease, of unknown etiology, that occurs almost exclusively in smokers.The clinical experience suggests a high prevalence of anxiety symptoms and an addictive profile. However, no study to date has precisely investigated the prevalence of co-morbid psychiatric disorders in this population.The aim of the study is to evaluate the prevalence of co-morbid psychiatric disorders in adult PLCH patients. This study should allow: * to assess the prevalence of psychiatric disorders co-morbid in PLCH patients * a targeted and more effective management of patients * a better response rate to smoking and cannabis weaning, that represents a major goal for these patients.
Interventions
OTHEREvaluation of co-morbid psychiatric disorders
Added scales : * Mini Internationnal Neuropsychiatric Interview * Fagerström test * DSM-5 Scale Additional dosage : - a urine sample will be taken to evaluate the presence of tobacco and nicotine breakdown products and the presence of various toxics Expired carbon monoxide for patients using nicotine substitutes
Sponsors
Assistance Publique - Hôpitaux de Paris
Study design
Observational model
OTHER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients of 18 years of age or older with PLCH diagnosed at adulthood * Patients affiliated to the French Health Care System * Informed patients
Exclusion criteria
* Patient unable to understand the interview (language barrier) * Patient under guardianship or curatorship * Patient under AME (French medical help for foreigners)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients with at least one of the disorders detailed in the Mini International Neuropsychiatric Interview (MINI) test | at inclusion | The Mini-International Neuropsychiatric Interview (M.I.N.I.) is a structured diagnostic interview (40 minutes duration), exploring in a standardized way the main psychiatric disorders of Axis I of the DSM-IV TR (American Psychiatric Association), namely 14 items with a binary result for each specified disorder |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients with active tobacco consumption with or without comorbid psychiatric disorder | at inclusion | Tobacco consumption will be assessed by Fagerström survey and DSM-5, cotinine in urine quantification and expired carbon monoxide for patients using nicotine substitutes. Fargerstrom test evaluates the dependence on cigarettes from 0 to 10 (0 indicated a very low dependence and 10 a very strong dependence) |
| Proportion of patients with persistent tobacco consumption despite nicotine replacement treatment | at inclusion | Tobacco consumption will be assessed by Fagerström survey and DSM-5 and expired carbon monoxide for patients with nicotine substitutes |
| Proportion of patients with at least one comorbid addictive disorder among: tobacco, alcohol, cannabis, benzodiazepines, cocaine, opiates | at inclusion | Definition and diagnosis of addictive disorder will be assessed with Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) |
| Number of co-morbid psychiatric disorders | at inclusion | — |
| Factors associated with psychiatric disorders as assessed by Mini International Neuropsychiatric Interview (MINI) test | at inclusion | The Mini-International Neuropsychiatric Interview (M.I.N.I.) is a structured diagnostic interview (40 minutes duration), exploring in a standardized way the main psychiatric disorders of Axis I of the DSM-IV TR (American Psychiatric Association), namely 14 items with a binary result for each specified disorder |
| Number of previous tobacco weaning episodes and co-morbid psychiatric disorders | at inclusion | — |
Countries
France
Contacts
Primary ContactAbdellatif TAZI
Backup ContactMatthieu Resche-Rigon, Pr
Outcome results
None listed